Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Bad financial results growth rate -2.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.6%)
  • Dividend yield for the last twelve months 5.1%
  • Free cash flow yield 7.4% (LTM)
  • Share price is 21.2% higher than minimum and 40.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (23.0x vs
    )

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+0.3%)48.085
year average price 52.10  


year start price 40.88 2024-06-06

min close price 39.66 2024-07-05

max close price 63.11 2025-03-10

current price 48.13 2025-06-05
Common stocks: 2 111 517 922

Dividend Yield:  5.1%
FCF Yield LTM: 7.4%
EV / LTM EBITDA: 23.0x
EV / EBITDA annualized: 11.8x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 101 532
Net Debt ($m): 38 895
EV (Enterprise Value): 140 427
EBITDA LTM ($m): 6 108
EV / LTM EBITDA: 23.0x
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-02zacks.com

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

2025-06-02youtube.com

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

2025-06-02youtube.com

Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

2025-06-02marketwatch.com

Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race

2025-06-02wsj.com

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

2025-05-29zacks.com

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

2025-05-28seekingalpha.com

Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

2025-05-28seekingalpha.com

Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy

2025-05-27seekingalpha.com

Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar

2025-05-27seekingalpha.com

Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data